Form 4: Vir Biotechnology Director Ramy Farid Granted 8,000 RSUs and 16,000 Stock Options

Vir Biotechnology, Inc. announced that Director Ramy Farid was granted 8,000 restricted stock units and 16,000 stock options, effective May 30, 2025, as part of the company's equity incentive plan.

Summary

• Ramy Farid, a Director at Vir Biotechnology, Inc., acquired 8,000 restricted stock units (RSUs) and 16,000 stock options on May 30, 2025.
• The RSUs were acquired at a price of $0 and are scheduled to vest in full on May 30, 2026.
• The stock options have an exercise price of $4.94 per share, will vest in full on May 30, 2026, and are set to expire on May 29, 2035.
• Following these transactions, Ramy Farid beneficially owns 24,000 shares of common stock and 16,000 stock options directly.
• These grants were made pursuant to the Issuer's Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a director, which is generally positive as it aligns interests and incentivizes long-term performance. There are no negative surprises or red flags.

Positives

• The grant of equity awards to a director aligns management's interests with shareholders, incentivizing long-term performance.
• The awards are part of the company's established Equity Incentive Plan, indicating a structured and transparent approach to executive compensation.

Negatives

• Potential for minor dilution from the future vesting of RSUs and exercise of stock options, which is a standard consideration for equity compensation.

Future Outlook

The vesting schedule for the granted restricted stock units and stock options indicates a future vesting event on May 30, 2026, aligning with long-term incentive goals.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director within the biotechnology sector. Such grants are common practice to attract and retain talent, and to align the interests of directors with those of shareholders, particularly in a research-intensive industry like biotechnology where long-term value creation is key.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a standard practice in the biotechnology industry for executive and director compensation.
• The specific amounts and vesting schedules are typically benchmarked against peer companies of similar size and stage of development, such as Moderna (MRNA), BioNTech (BNTX), or Gilead Sciences (GILD), to ensure competitive compensation packages that incentivize long-term performance and retention.
• Without specific compensation committee reports or peer group analysis, a direct comparison of the 'results' (i.e., the compensation package) to industry benchmarks is not fully possible from this Form 4 alone, but the type of compensation is consistent with industry norms.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for minor dilution upon vesting and exercise of equity awards, but also benefit from increased alignment of director's interests with long-term company performance.
• **Employees**: No direct impact on general employees, but reflects the company's approach to executive compensation.

Next Steps

• Vesting of 8,000 restricted stock units on May 30, 2026.
• Vesting and exercisability of 16,000 stock options on May 30, 2026.

Key Dates

Recommendation

Keywords

Vir Biotechnology, VIR, Ramy Farid, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director Compensation, Executive Compensation